Onco-Innovations Preps for Phase 1 as AI Partnerships and Lab Data Drive Share Recovery

Canadian biotech Onco-Innovations rallies 79% to €0.70, driven by IND manufacturing validation, PNKP animal studies, and AI collaborations with AstraZeneca and GSK. Nasdaq listing in sight.

Shares of Onco-Innovations have surged 79% over the past 30 days to close Friday at €0.70, as the Canadian biotech firm juggles a packed agenda of preclinical milestones, manufacturing scale-up, and high-profile artificial intelligence collaborations with Big Pharma. The rally marks a sharp rebound from the stock’s 52-week low of €0.35, though it remains well below the year’s peak of €1.49, underscoring the volatility that has become the company’s hallmark. With annualized volatility running at roughly 133%, investors are betting on a string of near-term catalysts to narrow the gap.

At the heart of the next few weeks is the validation of manufacturing processes required for an investigational new drug (IND) application. Onco-Innovations is standardising production of its active pharmaceutical ingredient, ONC010, to meet international quality standards — a prerequisite for the first clinical trials in humans. CEO Thomas O’Shaughnessy has described this step as the foundation for all subsequent progress, with authorities demanding exact, repeatable measurements before greenlighting Phase 1.

Parallel to the manufacturing push, contract research organisation Nucro-Technics is running animal models of the company’s PNKP inhibitor technology, collecting pharmacokinetic and biodistribution data. Those results are critical: they will underpin the toxicology studies that must clear the way for human testing. Meanwhile, partner Avance Clinical is preparing to meet the US Food and Drug Administration to align on study design. Onco-Innovations targets the launch of a Phase 1 trial in Australia in 2026, where it can claim research rebates of up to 43.5% on development costs.

On the corporate development front, the company’s AI subsidiary Inka Health Corp has deepened its ties with two pharmaceutical giants. A joint programme with AstraZeneca uses artificial intelligence to predict how well cancer therapies will work in individual patients. A separate agreement with GlaxoSmithKline focuses on mining real-world clinical data to improve how trial results translate to broader patient populations. The underlying data for these models comes from a pact with OneMedNet, giving Inka Health access to US oncology records, while Palantir’s technology platform supports the analytics. The goal across both collaborations is to shorten development timelines and cut risk by spotting patterns that traditional methods miss.

On the capital markets side, management is laying the groundwork for a secondary listing on the Nasdaq, with a US investment banker already engaged. In February 2026 the company filed a preliminary base prospectus in Canada that would permit future capital measures, though regulatory approval remains pending. The move is widely seen as a bid to tap deeper pools of US investors as the company transitions from a research-stage outfit to a clinical-stage biotech.

The immediate timetable hinges on two parallel tracks: Nucro-Technics must deliver robust laboratory data, and Avance Clinical needs to submit FDA documents on schedule. If both fall into place, the Phase 1 start in 2026 stays realistic, and the second quarter of this year could bring the most significant fundamental milestone the company has ever reported.